Want to see HK:2170 full AI Analyst Report?
2170 Stock Chart & Stats
HK$1.97
HK$0.20(8.26%)
At close: 4:00 PM EST
HK$1.97
HK$0.20(8.26%)
Day’s Range― - ―
52-Week RangeHK$1.23 - HK$4.36
Previous CloseN/A
Volume107.50K
Average Volume (3M)121.73K
Market Cap
HK$382.94M
Enterprise ValueHK$393.16
Total Cash (Recent Filing)HK$443.02M
Total Debt (Recent Filing)HK$343.36M
Price to Earnings (P/E)―
Beta1.34
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.82
Shares Outstanding82,713,840
10 Day Avg. Volume98,950
30 Day Avg. Volume121,733
Financial Highlights & Ratios
PEG Ratio0.35
Price to Book (P/B)0.49
Price to Sales (P/S)1.96
P/FCF Ratio-1.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$1.60Price Target Upside-18.78% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.23
Revenue Forecast (FY)HK$412.00M
Bulls Say, Bears Say
Bulls Say
Recurring Consumables RevenueA consumables-heavy revenue model creates repeatable, per-procedure demand from an installed base of clinics and labs. That recurring stream tends to be more predictable than one-time device sales, supporting durable revenue visibility and potential margin stability as volumes scale.
Product-level Gross MarginA near-50% gross margin indicates underlying product economics are healthy at the unit level. If management controls overhead and restores top-line growth, this product margin can be leveraged to recover operating profitability, making long-run break-even more attainable.
Balance Sheet CushionModerate leverage and substantial equity give the firm time to execute turnaround actions without imminent solvency pressure. This structural capital buffer reduces short-term default risk and allows incremental financing or operational adjustments to pursue sustainable recovery.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flows force reliance on external funding or asset measures. Over months this reduces strategic flexibility, increases dilution or leverage risk, and constrains the company's ability to invest in sales, quality controls, or R&D needed to regain growth.
Deep Operating And Net LossesVery large operating and net losses despite product gross margins signal that fixed costs, SG&A, or other expenses overwhelm revenue. Persisting at this scale will erode equity, impede reinvestment, and make achieving a sustainable business model difficult without structural cost or revenue changes.
Revenue Decline And Weak MomentumA sharp year-over-year revenue drop undermines scale advantages for consumables and drives operating leverage the wrong way. Continued top-line contraction makes margin recovery harder, increases per-unit fixed cost burdens, and raises the probability of further cash shortfalls.
Suzhou Basecare Medical Corp. Ltd. Class H News
2170 FAQ
What was Suzhou Basecare Medical Corp. Ltd. Class H’s price range in the past 12 months?
Suzhou Basecare Medical Corp. Ltd. Class H lowest stock price was HK$1.23 and its highest was HK$4.36 in the past 12 months.
What is Suzhou Basecare Medical Corp. Ltd. Class H’s market cap?
Suzhou Basecare Medical Corp. Ltd. Class H’s market cap is HK$382.94M.
When is Suzhou Basecare Medical Corp. Ltd. Class H’s upcoming earnings report date?
Suzhou Basecare Medical Corp. Ltd. Class H’s upcoming earnings report date is Aug 31, 2026 which is in 26 days.
How were Suzhou Basecare Medical Corp. Ltd. Class H’s earnings last quarter?
Suzhou Basecare Medical Corp. Ltd. Class H released its earnings results on Mar 30, 2026. The company reported -HK$0.408 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Suzhou Basecare Medical Corp. Ltd. Class H overvalued?
According to Wall Street analysts Suzhou Basecare Medical Corp. Ltd. Class H’s price is currently Overvalued.
Does Suzhou Basecare Medical Corp. Ltd. Class H pay dividends?
Suzhou Basecare Medical Corp. Ltd. Class H does not currently pay dividends.
What is Suzhou Basecare Medical Corp. Ltd. Class H’s EPS estimate?
Suzhou Basecare Medical Corp. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Suzhou Basecare Medical Corp. Ltd. Class H have?
Suzhou Basecare Medical Corp. Ltd. Class H has 82,713,840 shares outstanding.
What happened to Suzhou Basecare Medical Corp. Ltd. Class H’s price movement after its last earnings report?
Suzhou Basecare Medical Corp. Ltd. Class H reported an EPS of -HK$0.408 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.5%.
Which hedge fund is a major shareholder of Suzhou Basecare Medical Corp. Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2170
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Suzhou Basecare Medical Corp. Ltd. Class H Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.08%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-9.31%
Trailing 12-Months
Company Description
Suzhou Basecare Medical Corp. Ltd. Class H
Suzhou Basecare Medical Corporation Limited, an investment holding company established in Suzhou, China, in 2010, focuses its business activities within the People's Republic of China. The company primarily engages in the research, development, and manufacturing of genetic testing solutions specifically for assisted reproduction, alongside the distribution of related medical devices and instruments. Its extensive product line includes a range of genetic test kits for reproductive health. These comprise pre-implantation genetic tests such as PGT-A, designed to screen for chromosomal aneuploidies; PGT-M, which identifies single-gene or monogenic defects in pre-implantation embryos; and PGT-SR kits, used to detect chromosomal structural rearrangements often linked to recurrent miscarriages. Additionally, Basecare offers prenatal test kits (CNV kits) and postnatal test kits (WES kits). Complementing its genetic testing offerings, the company supplies various specialized medical equipment, including liquid nitrogen storage dewars, cryostorage systems, automated workstations, sperm quality analyzers, and next-generation sequencing (NGS) sequencers. Beyond manufacturing and sales, Basecare also provides marketing services and develops software for its medical devices and instruments. Its primary clientele consists of hospitals and reproductive clinics.
2170 Stock 12 Month Forecast
Average Price Target
HK$1.60
▼(-18.78% Downside)
Technical Analysis
MicroPort Scientific
―
LifeTech Scientific Corporation
―
AK Medical Holdings Ltd.
―
MicroPort CardioFlow Medtech Corp.
―
Venus Medtech (Hangzhou), Inc. Class H
―